<DOC>
	<DOCNO>NCT01339091</DOCNO>
	<brief_summary>The primary object compare early clinical efficacy ( 48-72 hour therapy ) dalbavancin comparator regimen ( vancomycin option switch oral linezolid ) treatment patient suspect proven gram-positive bacterial skin skin structure infection .</brief_summary>
	<brief_title>Efficacy Safety Dalbavancin Treatment Acute Bacterial Skin Skin Structure Infections</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Wound Infection</mesh_term>
	<mesh_term>Surgical Wound Infection</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Linezolid</mesh_term>
	<mesh_term>Vancomycin</mesh_term>
	<mesh_term>Dalbavancin</mesh_term>
	<mesh_term>Teicoplanin</mesh_term>
	<criteria>1 . Male female patient 18 85 year age . 2 . Signed date informed consent document . 3 . Major abscess , surgical site infection , traumatic wound infection cellulitis suspect confirm caused Grampositive bacteria . 4 . At least two ( 2 ) local sign symptom ABSSSI least one ( 1 ) systemic sign infection . 5 . Requires minimum 3 day IV therapy . 6 . Patient willing able comply study procedure . Patients present follow : 1 . A contraindication require study drug . 2 . Pregnant nursing female . 3 . Sustained shock . 4 . Participation another study investigational drug device within 30 day . 5 . Receipt systemically topically administer antibiotic within 14 day prior randomization , except receipt single dose shortacting antibacterial drug 3 day prior randomization . 6 . Infection due dalbavancin vancomycinresistant organism . 7 . Evidence meningitis , necrotizing fasciitis , gas gangrene , gangrene , septic arthritis , osteomyelitis , and/or endovascular infection . 8 . Exclusively gramnegative bacterial fungal ABSSSI . 9 . Venous catheter infection . 10 . Infection diabetic foot ulcer decubitus ulcer . 11 . Devicerelated infection . 12 . Gramnegative bacteremia . 13 . Infected burn . 14 . Infected limb critical ischemia . 15 . Superficial/simple skin skin structure infection . 16 . Concomitant condition require nonstudy antibacterial therapy . 17 . ABSSSI require therapy longer 14 day . 18 . Adjunctive therapy hyperbaric oxygen . 19 . More 2 surgical intervention ABSSSI anticipate . 20 . Chronic inflammatory condition preclude assessment clinical response . 21 . Absolute neutrophil count &lt; 500 cells/mm3 . 22 . Human immunodeficiency virus ( HIV ) infection CD4 cell count &lt; 200 cells/mm3 . 23 . Recent bone marrow transplant , &gt; 20 mg prednisolone per day ( equivalent ) receive immunosuppressant drug organ transplantation . 24 . Regular , chronic antipyretic use patient unable modify first three day study drug therapy . 25 . Life expectancy le 3 month . 26 . Conditions may increase risk associate study participation investigational product administration may interfere interpretation study result . 27 . Prior participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>